Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Model-Based Cost-Effectiveness Analysis of Atorvastatin Drugs for Prevention of Cardiovascular Diseases in Iran Publisher



Jabbari A1 ; Jafari A2 ; Hadian M3 ; Ghasemi M4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Health Management and Economics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Health Human Resources Research Center, School of Management and Medical Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
  3. 3. Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Member of Social Determinant of Health Center, Birjand University of Medical Sciences, Birjand, Iran

Source: International Journal of Preventive Medicine Published:2020


Abstract

Today, cardiovascular disease is one of the main causes of mortality and disability in most developed and developing countries. The prediction of the major causes of deaths all over the world at all ages shows that 61% of deaths are due to chronic diseases, of which 30% is due to cardiovascular disease. The aim of this study was to assess the cost-utility analysis of atorvastatin for the prevention of cardiovascular diseases using the Markov model. Methods: Markov model with a lifetime horizon was developed to evaluate economic and health outcomes for atorvastatin drugs for the prevention of cardiovascular diseases for a cohort of 1,000 patients. The effectiveness indicator in this study was quality-adjusted life-years (QALYs); robustness of results was examined by one-way and probabilistic sensitivity analysis. Results: The results showed that the use of atorvastatin compared to no drug intervention was highly cost-effective with USD173 per additional QALY. The results of one-way and probabilistic sensitivity analysis confirmed the results of this study. The findings of this study also showed that the highest cost items were hospitalization costs in the cardiac care unit (CCU). Also, the highest cost items in para-clinical services were related to echocardiography costs, and troponin constituted the largest cost of laboratory tests.Conclusions: Based on the results of this study, it is recommended that cardiologists use atorvastatin in the prevention of cardiovascular disease. © 2020 Wolters Kluwer Medknow Publications. All rights reserved.
Related Docs
View other Related Docs
1. Cost-Effectiveness and Cost-Utility Analysis of Otc Use of Simvastatin 10 Mg for the Primary Prevention of Myocardial Infarction in Iranian Men, DARU, Journal of Pharmaceutical Sciences (2015)
2. The Cost-Effectiveness and Cost-Utility of Statin Drug for the Treatment of Patients With Cardiovascular Disease, a Systematic Review, International Journal of Preventive Medicine (2021)
3. Coronary Bypass Surgery Versus Percutaneous Coronary Intervention: Cost-Effectiveness in Iran: A Study in Patients With Multivessel Coronary Artery Disease, International Journal of Technology Assessment in Health Care (2014)
4. Cost-Effectiveness Evaluation of Aspirin in Primary Prevention of Myocardial Infarction Amongst Males With Average Cardiovascular Risk in Iran, Research in Pharmaceutical Sciences (2017)
5. Total Cardiovascular Risk Approach to Improve Efficiency of Cardiovascular Prevention in Resource Constrain Settings, Journal of Clinical Epidemiology (2011)
6. Cost-Utility Analysis of Combination Medical Therapies in Chronic Coronary Syndrome: A Comparative Study Using Real-World and Patient-Level Data From Iran, BMJ Open (2025)
7. A Review of Fixed-Dose Combination Therapy for Secondary Prevention of Adverse Cardiovascular Events and the Preliminary Results of the Persianpolypill Randomized Clinical Trial; [کارآزمایی بالینی تصادفی Persianpolypill شدهی مروری بر درمان ترکیبی با دوز ثابت برای پیشگیری ثانویه از حوادث نامطلوب قلبی- عروقی و نتایج اولیهی], Journal of Isfahan Medical School (2024)
8. The Pattern of In-Hospital Mortality of Myocardial Infarction and Associated Factors in Iran: A National Study, Journal of Isfahan Medical School (2015)
Experts (# of related papers)
View all Related Experts
Nizal Sarrafzadegan (8)
Masoumeh Sadeghi (5)
Other Related Docs
9. The Cost-Effectiveness and Cost-Utility Analysis of the Use of Enoxaparin Compared With Heparin for Venous Thromboembolism Prophylaxis in Medical Inpatients in Iran, DARU, Journal of Pharmaceutical Sciences (2019)
10. Cost-Effectiveness of Hypertension Therapy Based on 2020 International Society of Hypertension Guidelines in Ethiopia From a Societal Perspective, PLoS ONE (2022)
11. Availability and Affordability of Medicines and Cardiovascular Outcomes in 21 High-Income, Middle-Income and Low-Income Countries, BMJ Global Health (2020)
12. Cardiovascular Disease Risk Assessment: Triglyceride/High-Density Lipoprotein Versus Metabolic Syndrome Criteria, Journal of Research in Health Sciences (2019)
13. Cardiac Rehabilitation Costs, International Journal of Cardiology (2017)
14. Risk of Fatal and Nonfatal Coronary Heart Disease and Stroke Events Among Adult Patients With Hypertension: Basic Markov Model Inputs for Evaluating Cost-Effectiveness of Hypertension Treatment: Systematic Review of Cohort Studies, Journal of Pharmaceutical Health Services Research (2021)
15. Effectiveness of Polypill for Primary and Secondary Prevention of Cardiovascular Diseases (Polyiran): A Pragmatic, Cluster-Randomised Trial, The Lancet (2019)
16. The Use and the Cost of Outpatient Diagnostic Procedures for Cardiovascular Diseases in Isfahan Province: A Utilization Study, Journal of Education and Health Promotion (2022)
17. Polypill for the Prevention of Cardiovascular Disease (Polyiran): Study Design and Rationale for a Pragmatic Cluster Randomized Controlled Trial, European Journal of Preventive Cardiology (2015)
18. Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-Income, Middle-Income, and Low-Income Countries: An Analysis of the Pure Study Data, The Lancet (2016)
19. The Prevalence of the Risk Factors Associated With Cardiovascular Diseases Among Iranian Adults: Findings of a Cross‑Sectional Study, Journal of Education and Health Promotion (2024)
20. Comparison of Models for Predicting Outcomes in Patients With Coronary Artery Disease Focusing on Microsimulation, International Journal of Preventive Medicine (2012)
21. Cost-Effectiveness and Cost-Utility Analysis of Type-2 Diabetes Screening in Pharmacies in Iran, Research in Pharmaceutical Sciences (2023)